BRPI0408494A - terapia combinada contra tumores compreendendo nemorubicina com terapia de radiação - Google Patents

terapia combinada contra tumores compreendendo nemorubicina com terapia de radiação

Info

Publication number
BRPI0408494A
BRPI0408494A BRPI0408494-2A BRPI0408494A BRPI0408494A BR PI0408494 A BRPI0408494 A BR PI0408494A BR PI0408494 A BRPI0408494 A BR PI0408494A BR PI0408494 A BRPI0408494 A BR PI0408494A
Authority
BR
Brazil
Prior art keywords
therapy
nemorubicin
radiation therapy
combined tumor
radiation
Prior art date
Application number
BRPI0408494-2A
Other languages
English (en)
Inventor
Maria Cristina Rosa Geroni
Maria Adele Pacciarini
Antonino Suarato
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of BRPI0408494A publication Critical patent/BRPI0408494A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"TERAPIA COMBINADA CONTRA TUMORES COMPREENDENDO NEMORUBICINA COM TERAPIA DE RADIAçãO". A presente invenção refere-se a um derivado morfolinil antraciclina para uso como rádio-sensibilizador, para administração combinada com terapia de radiação, de modo que possa ser revelado um efeito sinérgico.
BRPI0408494-2A 2003-03-18 2004-03-03 terapia combinada contra tumores compreendendo nemorubicina com terapia de radiação BRPI0408494A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03075781 2003-03-18
PCT/EP2004/050246 WO2004082579A2 (en) 2003-03-18 2004-03-03 Nemorubicin as radiosensitizer in combination with radiation therapy against tumors

Publications (1)

Publication Number Publication Date
BRPI0408494A true BRPI0408494A (pt) 2006-04-04

Family

ID=33016931

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408494-2A BRPI0408494A (pt) 2003-03-18 2004-03-03 terapia combinada contra tumores compreendendo nemorubicina com terapia de radiação

Country Status (8)

Country Link
EP (1) EP1603575A2 (pt)
AU (1) AU2004222526A1 (pt)
BR (1) BRPI0408494A (pt)
CA (1) CA2519289A1 (pt)
MX (1) MXPA05009851A (pt)
NO (1) NO20054349L (pt)
RU (1) RU2005132175A (pt)
WO (1) WO2004082579A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006292482A1 (en) * 2005-09-16 2007-03-29 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating or preventing cancer using pyridine carboxaldehyde pyridine thiosemicarbazone radiosensitizing agents
ES2552718T3 (es) 2007-05-11 2015-12-01 Nerviano Medical Sciences S.R.L. Composición farmacéutica de una antraciclina
US8742076B2 (en) 2008-02-01 2014-06-03 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
WO2010009124A2 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
ES2533710T3 (es) 2010-12-02 2015-04-14 Nerviano Medical Sciences S.R.L. Proceso para la preparación de derivados de morfolinil antraciclina
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
WO2016071418A1 (en) * 2014-11-05 2016-05-12 Nerviano Medical Sciences S.R.L. Functionalized morpholinyl anthracycline derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710564A (en) * 1985-01-18 1987-12-01 Microbial Chemistry Research Foundation Anthracycline compounds
GB2172594B (en) * 1985-03-22 1988-06-08 Erba Farmitalia New morpholino derivatives of daunorubicin and doxorubicin
GB2296495B (en) * 1994-12-23 1998-04-15 Erba Carlo Spa Anthracycline derivatives
GB2315067B (en) * 1996-07-11 2000-02-16 Pharmacia Spa Morpholinyl anthracycline derivatives
KR100968657B1 (ko) * 2002-04-02 2010-07-06 네르비아노 메디칼 사이언시스 에스.알.엘. 치환된 아크릴로일 디스타마이신 유도체 및 방사선요법을포함하는 조합 종양 치료법

Also Published As

Publication number Publication date
MXPA05009851A (es) 2005-12-06
CA2519289A1 (en) 2004-09-30
WO2004082579A2 (en) 2004-09-30
EP1603575A2 (en) 2005-12-14
WO2004082579A3 (en) 2004-11-11
NO20054349L (no) 2005-10-11
RU2005132175A (ru) 2006-01-27
AU2004222526A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
DK1689724T3 (da) Quinazolinonforbindelser som anticancermidler
BRPI0506977A (pt) composto de tetrahidrocarbolina como agentes anticáncer
CA2683786C (en) Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects
MX2009013989A (es) Terapia en combinacion para depresion.
UY28941A1 (es) Indazoles sustituidos, composiciones que los contienen, procedimiento de preparacion y su uso
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
AR071728A1 (es) Terapia con intervalos para el tratamiento del tinnitus
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
TW200505454A (en) Heteroaryl-fused pyrimidinyl compounds as anticancer agents
ECSP066378A (es) "un derivado de isoxazolina como un inhibidor contra varias caspasas, un procedimiento para preparar el mismo y una composicion terapeutica para prevenir la inflamacion y la apotosis que comprende el mismo"
CR20110553A (es) Terapia complementaria contra el cáncer
AR035293A1 (es) Composicion oftalmica.
MX2010005012A (es) Composiciones para el tratamieno y prevencion de inflamacion de los parpados que comprenden un ingrediente osmoticamente activo y un vasocosntrictor.
CR10996A (es) Metodo de tratamiento del cancer mediante administracion de combinaciones de il-18 humana
WO2005070043A3 (en) Methods for treating non-melanoma cancers with paba
ES2188261T3 (es) Tiomolibdato asociado a, al menos, un hidrato de carbono y su uso en la prevencion o tratamiento de enfermedades caracterizadas por una vacularizacion aberrante, tales como cancer, degeneracion macular tipo humedo, artritis reumatoides.
MX2007004955A (es) Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
TR200103271T2 (tr) İnflamasyon aracılığıyla gerçekleşen infeksiyon için anti-inflamatuar tedavi.
DK1827500T3 (da) Pegyleret liposomal doxorubicin i kombination med ecteinescidin 743
MXPA05009851A (es) Como radiosensibilizador en combinacion con terapia con radiacion contra tumores.
WO2007087462A3 (en) Methods and compositions for cancer therapy using a novel adenovirus
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
GT200500191A (es) Derivados de pirido - pirimidina, su preparacion, su aplicacion en terapeutica
ES2723778T3 (es) Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos
MX2008001661A (es) Metodos para tratar afecciones malignas de celulas b que utilizan una molecula de fusion del activador de transmembrana o interactor del ligando de ciclofilina de modulacion de calcio-ig.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]